The first, a dose-response study utilizing a glucagon formulation stabilized by DMSO (the previous formulation had an aqueous base), showed that MDG derived from this new preparation was safe and effective with the optimal dose being 150 μg.6 Another study of this same formulation demonstrated that MDG was useful for the treatment of mild hypoglycemia.19 The third study utilized a next- generation glucagon analog, dasiglucagon. The gene discussed is GCG; the disease is Hypoglycemia.